Subunit respiratory syncytial virus vaccine preparation
First Claim
Patent Images
1. A mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV).
0 Assignments
0 Petitions
Accused Products
Abstract
The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against decreased caused by respiratory syncytial virus infection.
2 Citations
36 Claims
- 1. A mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV).
-
14. A coisolated and copurified mixture of non-denatured proteins of respiratory syncytial virus (RSV), consisting essentially of the fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV, wherein the mixture is free from lectins and is free from monoclonal antibodies.
-
28. A method of producing a coisolated and copurified mixture of proteins of respiratory syncytial virus (RSV), which comprises:
-
growing RSV on cells in a culture medium;
separating the grown virus from the culture medium;
solubilizing at least the fusion (F) protein, attachment (G) protein and the matrix (M) protein from the separated virus; and
coisolating and copurifying the solubilized RSV proteins. - View Dependent Claims (29, 30, 31, 32)
-
-
36. A mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) for use as a pharmaceutical substance in a vaccine against disease caused by infection with respiratory syncytial virus.
Specification